Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 11/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 10/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 10/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 10/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 10/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 10/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 10/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 10/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 10/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 10/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 10/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | GSK3A | P49840 | 2/20 | 0.36 |
| ▸ | GSK3B | P49841 | 2/20 | 0.36 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.36 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4881325 | 0.79 | HDAC3 (0.44) | HDAC6HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL4883758 | 0.65 | SMN1; SMN2 (0.60) | HDAC6HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL2876591 | 0.64 | NCF1 (0.51) | ALDH1A1GSK3AGSK3BDYRK3PRKD3 | |
| SCHEMBL4880505 | 0.63 | HDAC3 (0.59) | HDAC6HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL16234628 | 0.63 | GSK3A (0.45) | GSK3AGSK3BDYRK3PRKD3MAP4K4 | |
| SCHEMBL4885795 | 0.62 | HDAC3 (0.47) | HDAC6HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL5761189 | 0.62 | L3MBTL1 (0.62) | HDAC6KDM4EGSK3AGSK3BDYRK3 | |
| SCHEMBL8366944 | 0.62 | NR1H2 (0.51) | KDM4EMAPTGSK3AGSK3BDYRK3 | |
| SCHEMBL4880410 | 0.62 | LMNA (0.53) | HDAC6HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL1091417 | 0.61 | NCF1 (0.51) | KDM4EMAPTGSK3AGSK3BDYRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194681-A1 | Novel Inhibitors of Histone Deacetylase for the Treatment of Disease | KALYPSYS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080194681-A1 | Novel Inhibitors of Histone Deacetylase for the Treatment of Disease | KALYPSYS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080194681-A1 | Novel Inhibitors of Histone Deacetylase for the Treatment of Disease | KALYPSYS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| EP-1819669-A2 | NOVEL INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | Kalypsys, Inc. (US) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006063294-A2 | NOVEL INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
| WO-2006063294-A2 | NOVEL INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194681-A1 | Novel Inhibitors of Histone Deacetylase for the Treatment of Disease | HDAC1, HDAC10, HDAC6 | HDAC6 3/4885HDAC3 11/4885HDAC4 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.